Xilio Therapeutics (XLO) Accumulated Expenses (2020 - 2026)

Xilio Therapeutics has disclosed Accumulated Expenses across 7 years of filings, most recently posting $9.0 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $9.0 million, up 131.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.0 million (up 131.01% YoY), and the FY2025 annual result was $11.7 million, up 17.61% from the prior year.
• Accumulated Expenses came in at $9.0 million for Q1 2026 at Xilio Therapeutics, down from $11.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.1 million in Q2 2022 to a low of $292000.0 in Q2 2024.
• The 5-year median for Accumulated Expenses is $9.0 million (2026), against an average of $7.8 million.
• Across the five-year window, Accumulated Expenses sank 95.91% in 2024 and jumped 1825.0% in 2025, its largest moves.
• Xilio Therapeutics' Accumulated Expenses stood at $10.3 million in 2022, then grew by 1.65% to $10.5 million in 2023, then dropped by 4.92% to $10.0 million in 2024, then rose by 17.61% to $11.7 million in 2025, then retreated by 23.59% to $9.0 million in 2026.
• The last three Accumulated Expenses figures came in at $9.0 million (Q1 2026), $11.7 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.